Newfund announced the close of Heka, a €60 million fund dedicated to braintech, marking one of the first funds in Europe focused exclusively on digital solutions for brain health.
Named after the Egyptian deity of medicine, the Heka fund is designed to back European startups developing technologies across psychiatric and neurological care, while supporting their expansion into the United States.
Newfund has already deployed capital into nine portfolio companies through the fund, with eight operating in major U.S. innovation hubs such as San Francisco and Boston. Two of these companies received FDA clearance in 2025, underscoring early traction in regulated healthcare markets.
The portfolio spans a range of applications, including AI-powered medical imaging used in clinical settings and digital therapeutics that leverage interactive technologies such as video games to treat conditions like severe depression.
The fund is focused on bridging a longstanding gap in the European ecosystem, where strong neuroscience research has historically outpaced the availability of venture funding needed to translate scientific advances into scalable healthcare companies.
By combining capital with operational support, Newfund aims to help founders navigate clinical validation, regulatory pathways, and commercialization, particularly in the U.S., where adoption and reimbursement opportunities are more mature.
The launch of Heka reflects growing investor interest in brain health, as neurological and psychiatric conditions represent some of the most complex and costly challenges in global healthcare.
